Challenge:
Our client hoped to create value from an acquired drug through additional claims but the drug product supplier advised our client that the challenging new formulation could not be developed in time. Our client had limited formulation capability and needed to consider possible alternatives to support their clinical strategy and timeline.
|
Solution:
Our team of formulation experts identified high probability options and ruled out more risky strategies to meet the tight timeline, providing the development path towards a commercial formulation.
|
Benefit:
Our client is now pursuing alternatives in parallel with clear decision points and a high probability of meeting their target date for beginning clinical studies.
|
